Abstract: New use of ADAMTS13 in the clinical filed is provided. The use of ADAMTS13 as a biomarker for monitoring the onset of liver damage, hepatic ischemia/reperfusion injury or the liver function after liver transplantation: a method of testing liver damage, a method of testing hepatic ischemia/reperfusion injury, or a method of testing the liver function after liver transplantation, each of the methods comprising measuring or monitoring the ADAMTS13 activity in a sample from a mammal; an agent for treating diseases selected from the group consisting of liver damage, hepatic ischemia/reperfusion injury and hepatic dysfunction after liver transplantation, which comprises ADAMTS13 or a mutant of ADAMTS13 as an effective ingredient.

Abstract: New use of ADAMTS13 in the clinical filed is provided. The use of ADAMTS13 as a biomarker for monitoring the onset of liver damage, hepatic ischemia/reperfusion injury or the liver function after liver transplantation: a method of testing liver damage, a method of testing hepatic ischemia/reperfusion injury, or a method of testing the liver function after liver transplantation, each of the methods comprising measuring or monitoring the ADAMTS13 activity in a sample from a mammal; an agent for treating diseases selected from the group consisting of liver damage, hepatic ischemia/reperfusion injury and hepatic dysfunction after liver transplantation, which comprises ADAMTS13 or a mutant of ADAMTS13 as an effective ingredient.

Abstract: New use of ADAMTS13 in the clinical filed is provided. The use of ADAMTS13 as a biomarker for monitoring the onset of liver damage, hepatic ischemia/reperfusion injury or the liver function after liver transplantation: a method of testing liver damage, a method of testing hepatic ischemia/reperfusion injury, or a method of testing the liver function after liver transplantation, each of the methods comprising measuring or monitoring the ADAMTS13 activity in a sample from a mammal; an agent for treating diseases selected from the group consisting of liver damage, hepatic ischemia/reperfusion injury and hepatic dysfunction after liver transplantation, which comprises ADAMTS13 or a mutant of ADAMTS13 as an effective ingredient.

Abstract: A monitor is arranged on the opposite side of a surgery table to a main doctor so that an assistant is able to view a surgery area directly without being blocked by the monitor. A camera has a working distance of more than or equal to 60 cm and is therefore above a view field for the main doctor to view the monitor, so that the visibility of the monitor is not hindered. The working distance is not more than 100 cm so that the resolution of the camera is not lowered too much.

Abstract: Provided are a morbidity diagnosis support system, a morbidity diagnosis data-generating system, and a morbidity diagnosis support method that are capable of supporting a highly reliable morbidity diagnosis. A morbidity diagnosis support system includes an extension device for extending a tissue section of cells, an image-photographing device for acquiring image data by image-photographing the tissue section, an image analysis device for analyzing the image data to calculate an index of morbidity based on a mode of cracks generated in the tissue section by the extension, and an output device for outputting the calculated index.

Abstract: New use of ADAMTS13 in the clinical filed is provided. The use of ADAMTS13 as a biomarker for monitoring the onset of liver damage, hepatic ischemia/reperfusion injury or the liver function after liver transplantation: a method of testing liver damage, a method of testing hepatic ischemia/reperfusion injury, or a method of testing the liver function after liver transplantation, each of the methods comprising measuring or monitoring the ADAMTS13 activity in a sample from a mammal; an agent for treating diseases selected from the group consisting of liver damage, hepatic ischemia/reperfusion injury and hepatic dysfunction after liver transplantation, which comprises ADAMTS13 or a mutant of ADAMTS13 as an effective ingredient.

Abstract: Provided are a morbidity diagnosis support system, a morbidity diagnosis data-generating system, and a morbidity diagnosis support method that are capable of supporting a highly reliable morbidity diagnosis. A morbidity diagnosis support system includes an extension device for extending a tissue section of cells, an image-photographing device for acquiring image data by image-photographing the tissue section, an image analysis device for analyzing the image data to calculate an index of morbidity based on a mode of cracks generated in the tissue section by the extension, and an output device for outputting the calculated index.

Abstract: The present application provides a method for preventing or protecting an organ from ischemia-reperfusion injury, the method comprising a step of perfusing an organ harvested for transplant ex vivo with a solution containing molecular hydrogen via a blood vessel thereof.

Abstract: The present invention provides magnetic iron oxide particles having a high bonding property to a resin as well as a magnetic carrier for electrophotographic developers which is improved in durability by enhancing adhesion between a magnetic carrier core material and a coating resin. The magnetic iron oxide particles of the present invention are magnetic iron oxide particles having an average particle diameter of 0.5 to 30 ?m onto which a plurality of granules are bonded, and the magnetic carrier for electrophotographic developers according to the present invention is a magnetic carrier for electrophotographic developers which comprises spherical magnetic composite particles produced by dispersing magnetic iron oxide particles in a binder resin in which the magnetic iron oxide particles comprise at least the above magnetic iron oxide particles having an average particle diameter of 0.5 to 30 ?m onto which the plurality of granules are bonded.

Abstract: Black magnetic iron oxide particles having an average particle diameter of 0.05 to 2.0 ?m and an electric resistance value at an applied voltage of 100 V of not less than 1×108 ?·cm. Also a magnetic carrier for electrophotographic developer having spherical magnetic composite particles obtained by dispersing black magnetic iron oxide particles in a binder resin. The magnetic carrier has an electric resistance value R100 at an applied voltage of 100 V of 1×108 to 1×1014 ?·cm, and an electric resistance value R300 at an applied voltage of 300 V which satisfies the relationship represented by the formula: 0.1?R300/R100?1.

Abstract: According to embodiments, a method of producing insulin-producing tissues (IPTs) by culturing comprises: preparing non-endocrinal epithelial cells (NEECs) and vascular endothelial cells (VECs), which have been isolated or originated from postnatal pancreata, preferably by capturing of NEECs by collagen; culturing in vitro the NEECs and the VECs at least partly separately from each other; and then generating in vitro a tissue complex (IPTs) that contains both the NEECs and the VECs. In another embodiment, the native islet cells are seeded on a monolayer of VECs that have preferably been separately cultured and purified. In a further embodiment, a method of enriching NEECs comprises: culturing NEECs adhering to a container or substrate; removing NEECs by treating with a tissue-dissociation enzyme to leave left-over cells (LOCs) still attached on the container or substrate; and culturing NEECs in a medium conditioned by, or in the presence of the LOCs.

Abstract: The present invention relates to a magnetic carrier for an electrophotographic developer comprising spherical composite particles comprising spherical composite core particles comprising at least ferromagnetic iron oxide fine particles and a cured phenol resin and having an average particle diameter of 1 to 100 ?m, and a melamine resin coating layer formed on the respective core particles, wherein a ratio of R100 to R300 (R100/R300) in which R100 is an electric resistance value as measured when applying a voltage of 100 V to the magnetic carrier; and R300 is an electric resistance value as measured when applying a voltage of 300 V to the magnetic carrier, is controlled to lie within the range of 1 to 50.

Abstract: The present invention provides magnetic iron oxide particles having a high bonding property to a resin as well as a magnetic carrier for electrophotographic developers which is improved in durability by enhancing adhesion between a magnetic carrier core material and a coating resin. The magnetic iron oxide particles of the present invention are magnetic iron oxide particles having an average particle diameter of 0.5 to 30 ?m onto which a plurality of granules are bonded, and the magnetic carrier for electrophotographic developers according to the present invention is a magnetic carrier for electrophotographic developers which comprises spherical magnetic composite particles produced by dispersing magnetic iron oxide particles in a binder resin in which the magnetic iron oxide particles comprise at least the above magnetic iron oxide particles having an average particle diameter of 0.5 to 30 ?m onto which the plurality of granules are bonded.

Abstract: According to embodiments, a method of producing insulin-producing tissues (IPTs) by culturing comprises: preparing non-endocrinal epithelial cells (NEECs) and vascular endothelial cells (VECs), which have been isolated or originated from postnatal pancreata, preferably by capturing of NEECs by collagen; culturing in vitro the NEECs and the VECs at least partly separately from each other; and then generating in vitro a tissue complex (IPTs) that contains both the NEECs and the VECs. In another embodiment, the native islet cells are seeded on a monolayer of VECs that have preferably been separately cultured and purified. In a further embodiment, a method of enriching NEECs comprises: culturing NEECs adhering to a container or substrate; removing NEECs by treating with a tissue-dissociation enzyme to leave left-over cells (LOCs) still attached on the container or substrate; and culturing NEECs in a medium conditioned by, or in the presence of the LOCs.

Abstract: The present invention relates to a magnetic carrier for an electrophotographic developer comprising spherical composite particles comprising spherical composite core particles comprising at least ferromagnetic iron oxide fine particles and a cured phenol resin and having an average particle diameter of 1 to 100 ?m, and a melamine resin coating layer formed on the respective core particles, wherein a ratio of R100 to R300 (R100/R300) in which R100 is an electric resistance value as measured when applying a voltage of 100 V to the magnetic carrier; and R300 is an electric resistance value as measured when applying a voltage of 300 V to the magnetic carrier, is controlled to lie within the range of 1 to 50.

Abstract: There are provided black iron-based particles comprising iron/titanium composite oxide particles having a titanium element content (A) of 5 to 35% by atom based on an iron element content contained in the black iron-based particles, and a ratio of a titanium element content (B) (based on an iron element content contained in the portion dissolved) in a portion of the black iron-based particles, which is dissolved therefrom at an iron element dissolution percentage of 1% by weight, to the titanium content (A) of not less than 1.0. The black iron-based particles of the present invention are not only excellent in dispersibility, acid resistance, tinting strength and blackness, but also exhibit a less magnetization value. Also, the black paint and the rubber or resin composition of the present invention are excellent in acid resistance and blackness.

Abstract: According to the present invention, a method of detecting water leakage in a coil, which determines whether or not cooling water leaks into an insulation layer, the water being supplied to a conductor of a coil covered with the insulation layer, including: applying an AC voltage to the conductor; bringing a surface electrode device into pressure contact with the insulation layer; grounding the surface electrode device through an impedance; measuring a potential of the surface electrode device; and determining that the cooling water leaks from the conductor into the insulation layer when a measured potential is higher than a potential of a normal coil

Abstract: There are provided a pharmaceutical raw material capable of exhibiting a uniform functionality and producing magnetic particle-containing drugs for diagnosis and medical treatments with a high reproducibility. The pharmaceutical raw material comprises a monodisperse colloid sterile aqueous solution of magnetic iron oxide fine particles having an average particle diameter of 5 to 30 nm, a saturation magnetization of 50 to 90 Am2/kg and a coercive force of 0.1 to 1.6 kA/m. The pharmaceutical raw material can be produced by forming magnetic iron oxide fine particles in the form of a colloid aqueous solution, purifying the resultant colloid aqueous solution of superparamagnetic iron oxide particles by water-washing and removing water-soluble salts by-produced upon the reaction from the reaction solution by an ordinary method, and replacing a dispersing medium of the purified colloid aqueous solution with ultrapure water.

Abstract: The present invention relates to black magnetic iron oxide particles having an average particle diameter of 0.05 to 2.0 ?m and an electric resistance value at an applied voltage of 100 V of not less than 1×108 ?·m; and a magnetic carrier for electrophotographic developer comprising spherical magnetic composite particles obtained by dispersing black magnetic iron oxide particles in a binder resin, wherein the magnetic carrier has an electric resistance value R100 at an applied voltage of 100 V of 1×108 to 1×1014 ?·m, and an electric resistance value R300 at an applied voltage of 300 V which satisfies the relationship represented by the formula: 0.1?R300/R100?1.

Abstract: The present invention relates to a black magnetic iron oxide particles each having a polyhedral shape wherein when a percentage of dissolution of iron element based on a total amount of iron element contained in the black magnetic iron oxide particles is 50%, a percentage of dissolution of sulfur element based on a total amount of sulfur element contained in the black magnetic iron oxide particles is less than 40%.